Effects of Oxytocin on the Human Abuse Liability of Methamphetamine
催产素对人类滥用甲基苯丙胺的影响
基本信息
- 批准号:8892475
- 负责人:
- 金额:$ 24.3万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-09-30 至 2017-08-31
- 项目状态:已结题
- 来源:
- 关键词:Active ImmunizationAcuteAttenuatedBehavioralBudgetsCardiovascular systemClinicalClinical ResearchClinical TrialsCocaineDevelopmentDiseaseDopamineDoseDouble-Blind MethodDrug FormulationsExtinction (Psychology)FDA approvedFundingFutureGlutamatesHourHumanHyperactive behaviorIndividualInjectableInjection of therapeutic agentLaboratory StudyMeasuresMeta-AnalysisMethamphetamineMethamphetamine dependenceModelingNeuropeptidesOralOxytocinParticipantPatientsPharmaceutical PreparationsPharmacological TreatmentPharmacotherapyPlacebo ControlPlacebosProceduresPsychological reinforcementPublic HealthRandomizedRattusRelative (related person)ResearchResourcesRodentRoleRouteSelf AdministrationSeriesSerotoninSmokeStressUnited StatesUnited States National Institutes of HealthWorkbasebehavioral pharmacologyblinddesigndrug reinforcementeconomic valuemethamphetamine abusemethamphetamine usepre-clinical researchpreclinical studypreferencepublic health relevancereinforcer
项目摘要
DESCRIPTION (provided by applicant): Methamphetamine abuse and dependence are persistent public health issues in the United States. To date, no medications have been approved by the FDA for the treatment of methamphetamine use disorders. This clinical study will examine a promising medication for methamphetamine use disorders with strong support from preclinical research. Recently, the neuropeptide oxytocin has been identified as a promising candidate for methamphetamine use disorder pharmacotherapy. Preclinical studies with rodents have found that oxytocin decreases the reinforcing efficacy of methamphetamine by reducing methamphetamine self-administration, stress- and drug-primed reinstatement, and conditioned place preference (Carson et al., 2010a; Qi et al., 2009). Oxytocin has also been shown to decrease hyperactivity induced by methamphetamine and cocaine in rats (Carson et al., 2010a; Qi et al., 2009; Kovacs et al., 1990; Sarnyai, 1998). The proposed clinical study draws on these findings to determine the effects of acute oxytocin administration on the human abuse liability of two methamphetamine doses shown to have dose-dependent abuse-liability effects in previous human behavioral pharmacology research (Hart et al., 2002). In a double-blind, randomized, within-subject, placebo- controlled design, 18 healthy non-treatment seeking stimulant using individuals will be administered either oxytocin (24 IU, intranasal) or placebo prior to receiving methamphetamine (10 or 20 mg, oral) or placebo across 6 sessions. Measures will include abuse-liability related subject-rated effects of methamphetamine (e.g., "drug liking"). We hypothesize that oxytocin will decrease subject-rated abuse liability ratings fo both methamphetamine doses. However, because a reduction in subject-rated effects without a change in drug reinforcement may not predict efficacy in clinical trials (Hart et al., 2004; Hart e al., 2007a, 2007b; Bisaga et al., 2006), a drug vs. money choice procedure (the "multiple-choice procedure"; Griffiths et al., 1993) will determine drug reinforcement effects in each of the initia 6 sessions. That is, each participant will make a series of choices between receiving the drug(s) administered on that session once again vs. receiving various amounts of money. One of the drug vs. money choices across the 6 sessions will be randomly selected to be delivered in a 7th session. If the preference was money, then in the 7th session the participant would receive that amount in addition to unblinded intranasal and oral placebos. We hypothesize that, relative to placebo, oxytocin will decrease the reinforcer efficacy (i.e., monetary value) of both methamphetamine doses. The study will determine if larger resources should be devoted to developing oxytocin as a methamphetamine use disorder medication, including clinical trials in treatment-seeking methamphetamine-dependent individuals. This study may therefore substantially advance the field of pharmacotherapy for methamphetamine use disorders.
描述(由申请人提供):甲基苯丙胺滥用和依赖是美国持续存在的公共卫生问题。迄今为止,FDA尚未批准任何药物用于治疗甲基苯丙胺使用障碍。这项临床研究将在临床前研究的有力支持下,研究一种有前途的甲基苯丙胺使用障碍药物。最近,神经肽催产素已被确定为甲基苯丙胺使用障碍药物治疗的一个有前途的候选人。对啮齿动物的临床前研究已经发现,催产素通过减少甲基苯丙胺自我给药、应激和药物引发的恢复以及条件性位置偏好来降低甲基苯丙胺的增强功效(卡森等人,2010 a; Qi等人,2009年)。催产素还显示出减少大鼠中由甲基苯丙胺和可卡因诱导的活动过度(卡森等人,2010 a; Qi等人,2009; Kovacs等人,1990; Sarnyai,1998)。所提出的临床研究利用这些发现来确定急性催产素施用对两种甲基苯丙胺剂量的人类滥用倾向的影响,所述两种甲基苯丙胺剂量在先前的人类行为药理学研究中显示具有剂量依赖性滥用倾向效应(哈特等人,2002年)。在一项双盲、随机、受试者内、安慰剂对照设计中,18名健康的非寻求治疗的兴奋剂使用者将在接受甲基苯丙胺(10或20 mg,口服)或安慰剂之前,在6个疗程中给予催产素(24 IU,鼻内)或安慰剂。措施将包括与滥用责任有关的甲基苯丙胺的受试者评级影响(例如,“药物喜好”)。我们假设催产素会降低两种甲基苯丙胺剂量的受试者滥用倾向评级。然而,由于受试者评定效应的降低而不改变药物强化可能不能预测临床试验中的功效(哈特等人,2004;哈特等人,2007 a,2007 b; Bisaga等人,2006),药物与金钱选择程序(“多项选择程序”; Griffiths等人,1993年)将确定药物强化的影响,在每一个第六届会议。也就是说,每个参与者将在再次接受该疗程中给予的药物与接受各种金额之间做出一系列选择。在6个疗程中,将随机选择一个药物与金钱的选择,在第7个疗程中进行。如果偏好是金钱,则在第7阶段,除揭盲鼻内和口服安慰剂外,受试者还将获得该金额。我们假设,相对于安慰剂,催产素会降低催产素的疗效(即,货币价值)。这项研究将确定是否应该投入更多的资源来开发催产素作为甲基苯丙胺使用障碍药物,包括在寻求治疗的甲基苯丙胺依赖者中进行临床试验。因此,这项研究可能会大大推进甲基苯丙胺使用障碍的药物治疗领域。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Matthew Wayne Johnson其他文献
Matthew Wayne Johnson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Matthew Wayne Johnson', 18)}}的其他基金
5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder
5-HT2A 激动剂裸盖菇素治疗烟草使用障碍
- 批准号:
10187739 - 财政年份:2021
- 资助金额:
$ 24.3万 - 项目类别:
5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder
5-HT2A 激动剂裸盖菇素治疗烟草使用障碍
- 批准号:
10491336 - 财政年份:2021
- 资助金额:
$ 24.3万 - 项目类别:
Greenwashing cigarettes: Perceptual and behavioral evidence of inaccurate modified risk advertising
漂绿香烟:不准确的改良风险广告的感知和行为证据
- 批准号:
9980558 - 财政年份:2020
- 资助金额:
$ 24.3万 - 项目类别:
Greenwashing cigarettes: Perceptual and behavioral evidence of inaccurate modified risk advertising
漂绿香烟:不准确的改良风险广告的感知和行为证据
- 批准号:
10170306 - 财政年份:2020
- 资助金额:
$ 24.3万 - 项目类别:
Dose effects of nicotine: Behavioral economics of cigarette abuse liability
尼古丁的剂量效应:香烟滥用倾向的行为经济学
- 批准号:
9335825 - 财政年份:2016
- 资助金额:
$ 24.3万 - 项目类别:
Effects of Oxytocin on the Human Abuse Liability of Methamphetamine
催产素对人类滥用甲基苯丙胺的影响
- 批准号:
9145159 - 财政年份:2015
- 资助金额:
$ 24.3万 - 项目类别:
Cognitive Training in Adolescents during Treatment for Substance Use Disorders
青少年药物使用障碍治疗期间的认知训练
- 批准号:
8430475 - 财政年份:2013
- 资助金额:
$ 24.3万 - 项目类别:
Development of a Prospective Memory Intervention to Reduce Drug Use and HIV Risk
开发前瞻性记忆干预措施以减少吸毒和艾滋病毒风险
- 批准号:
8735112 - 财政年份:2013
- 资助金额:
$ 24.3万 - 项目类别:
Development of a Prospective Memory Intervention to Reduce Drug Use and HIV Risk
开发前瞻性记忆干预措施以减少吸毒和艾滋病毒风险
- 批准号:
8480249 - 财政年份:2013
- 资助金额:
$ 24.3万 - 项目类别:
Cognitive Training in Adolescents during Treatment for Substance Use Disorders
青少年药物使用障碍治疗期间的认知训练
- 批准号:
8660055 - 财政年份:2013
- 资助金额:
$ 24.3万 - 项目类别:
相似海外基金
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 24.3万 - 项目类别:
Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 24.3万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 24.3万 - 项目类别:
Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 24.3万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 24.3万 - 项目类别:
Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 24.3万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 24.3万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 24.3万 - 项目类别:
Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 24.3万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
- 批准号:
2244994 - 财政年份:2023
- 资助金额:
$ 24.3万 - 项目类别:
Standard Grant